CA-ADVA
10.3.2021 19:02:07 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has jointly won two awards at the MEF 3.0 Proof of Concept (PoC) Showcase. The honors recognize innovation and leadership with emerging services and technologies involving AI, SD-WAN, service automation and more. The Judge’s Choice Award for the best overall PoC was presented to a multi-vendor solution using ADVA’s Ensemble NFV suite to deliver personalized and automatically generated live video content over optimized network slices. Leveraging AI video technology and uCPE hosting SD-WAN, the demo showed how service providers can meet demand for unique immersive experiences of events such as live sports. ADVA also won the Market Game Changer Award, recognizing the largest potential impact on the service provider market. This was presented for its collaboration on a PoC using ADVA Ensemble software to enable multi-edge cloud services. This technology will be key to empowering enterprises to provide low-latency, high-throughput applications such as smart factories and industrial IoT.
“Our award-winning demo, Revolutionizing Live Events, illustrates how cable network operators can deliver exciting new services in an entirely original way. We’ve shown that it’s now possible to offer a unique, differentiated experience of live events that puts audiences at the heart of the action. Sports or music fans could soon be selecting their own viewing angles and receiving coverage that automatically zooms and tracks in real time. And for service providers, this points to a simple and cost-effective way of enabling high-volume, high-margin entertainment services,” said James Buchanan, GM, Edge Cloud, ADVA. “We’ve shown that utilizing uCPE and network slicing over enterprise networks can transform the way video content is produced and distributed. This cloud-based, virtualized approach opens the door to new levels of flexibility and automation for video services. What’s more, it highlights the potential of uCPE as a platform for innovation ready to unleash an array of new applications and business models.”
Featuring ADVA’s Ensemble suite of NFV software, the Revolutionizing Live Events PoC highlighted new opportunities for service providers to meet the growing expectations of sports and entertainment audiences. Driven by compute-based AI/ML, MEF-defined network slicing and lightweight uCPE running SD-WAN, the demo showed how network resources can be utilized to provide automated, highly personalized video content.
ADVA’s other award-winning PoC was the Orchestrated Multi-Edge Clouds demo. For this, the Ensemble NFV suite was deployed to manage and orchestrate SD-WAN, IoT, 5G networking and other edge-cloud technologies, seamlessly enabling the distribution of smart manufacturing resources between on-premises and network edge cloud environments. This demo paves the way for enterprises to purchase mission-critical applications and services flexibly and on demand.
“Our multi-edge cloud MEF 3.0 PoC is a key step in helping businesses to improve operational efficiency as they continue to digitize and automate their processes. It shows how service providers can accelerate adoption of multi-edge cloud services through the orchestration of applications and connectivity on open edge compute platforms. Winning the Market Game Changer Award underlines the impact on enterprises of being able to instantly purchase applications such as IoT, SD-WAN and wireless network access from a single managed service provider and have them automatically deployed across multiple cloud platforms,” commented Mike Heffner, VP, product line management, Edge Cloud, ADVA. “Using our Ensemble NFV software, this PoC proves that it’s now possible to relieve businesses of the responsibility and burden of multi-vendor system integration. This creates a major opportunity for service providers. They can offer on-demand, managed edge services and connectivity on open edge compute platforms that can be deployed in multiple locations. And, using advanced analytics, they can select the best edge location for IoT applications to meet SLAs.”
More information about the Revolutionizing Live Events PoC is available here: https://adva.li/mef-poc-live-events .
Further details on the Orchestrated Multi-Edge Clouds demo can be viewed here: https://adva.li/mef-poc-multi-edge-clouds .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005482/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom